Artificial blood vessel and preparation method thereof

A technology for artificial blood vessels and tube walls, applied in the field of artificial blood vessels and its preparation, can solve the problems of poor mechanical properties of artificial blood vessels, low vascular patency, weak anticoagulant function, etc., and achieve good clinical application prospects, high patency, The effect of good anticoagulant function

Active Publication Date: 2017-01-04
海迈医疗科技(苏州)有限公司
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In view of the above defects or improvement needs of the prior art, the present invention provides an artificial blood vessel and its preparation method, the purpose of which is to obtain an artificial blood vessel by decellularizing and coval

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Artificial blood vessel and preparation method thereof
  • Artificial blood vessel and preparation method thereof
  • Artificial blood vessel and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0047] The concrete steps of artificial blood vessel preparation method of the present invention are as follows:

[0048] (1) Preparation of autologous tissue pipeline

[0049] Cut the Teflon (Teflon) tube whose diameter matches the inner diameter of the blood vessel to be replaced to an appropriate length, sterilize it with 75% alcohol for 30 minutes, place it in the subcutaneous tissue, and take it out after 2 to 5 weeks, preferably 4 weeks. The surrounding newborn tissue was taken out, and the Teflon tube was extracted to obtain the autologous tissue pipeline. The thickness of the autologous tissue pipeline and the final artificial vascular product corresponding to 4 weeks are the most suitable, and the corresponding artificial vascular product has the best performance.

[0050] (2) Decellularization treatment

[0051] (2-1) Configuration of decellularization reagent: 3-[(3-cholamidopropyl)-diethylamine]-propanesulfonic acid (abbreviated as CHAPS reagent), EDTA.Na2, NaCl,...

Embodiment 1

[0064] (1) Preparation of autologous tissue pipeline

[0065] Cut a Teflon tube with a diameter matching the inner diameter of the blood vessel to be replaced to a suitable length, sterilize it with 75% alcohol for 30 minutes, and place it in the subcutaneous tissue. After 4 weeks, take out the subcutaneous Teflon tube together with the surrounding new tissue, and draw it out. In addition to the Teflon tube, an autologous tissue tube was obtained, the thickness of which was 324.1±57.4 microns (n=6, n is the number of test samples, and n has the same meaning below).

[0066] (2) Decellularization treatment

[0067] (2-1) Configuration of decellularization reagent

[0068]

[0069] According to the formula in the above table, add the accurately weighed reagent into a clean wide-mouth glass bottle, shake on the shaker for 2-3 hours to fully dissolve the reagent, at this time the solution becomes clear, prepare the decellularization reagent, and store it at 4°C for later use ...

Embodiment 2

[0083] (1) Preparation of autologous tissue pipeline

[0084] Cut the Teflon tube whose diameter matches the inner diameter of the blood vessel to be replaced to an appropriate length, sterilize it with 75% alcohol for 30 minutes, and place it in the subcutaneous tissue. After 2 weeks, take out the subcutaneous Teflon tube together with the surrounding new tissue, and draw it out. In addition to Teflon tubes, autologous tissue tubes were obtained with a thickness of 154.3±56.4 microns (n=6).

[0085] (2) Decellularization treatment

[0086] (2-1) Configuration of decellularization reagent

[0087]

[0088] According to the formula in the above table, add the accurately weighed reagent into a clean wide-mouth glass bottle, shake on the shaker for 2-3 hours to fully dissolve the reagent, at this time the solution becomes clear, prepare the decellularization reagent, and store it at 4°C for later use .

[0089] (2-2) Decellularization of autologous tissue pipeline

[0090]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses an artificial blood vessel and a preparation method thereof. Cell components of an autologous-tissue vessel are removed by adopting a 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate reagent chemical decellularization method; then heparin is combined to the surface of an autologous decellularized matrix vessel in a covalent binding manner, so as to obtain the artificial blood vessel. The artificial blood vessel prepared by the method has no immunogenicity; a preparation period is short and the cost is low; the artificial blood vessel can be prepared into different inner diameters and has a good anticoagulation function; a complicated in-vitro preparation process is not needed and the patency rate is high; cells can effectively enter a vessel wall to be reconstructed and the artificial blood vessel is completely better than previous allogenic or heterogeneous decellularized matrix vessels and has a very good clinical application prospect.

Description

technical field [0001] The invention belongs to the field of tissue engineering blood vessels, and more specifically relates to an artificial blood vessel and a preparation method thereof. Background technique [0002] At present, autogenous blood vessels such as the great saphenous vein and the internal mammary artery are the most important graft vessels clinically used in coronary artery bypass surgery and other small-caliber vessel bypass surgery. The two small-bore blood vessels of acellular matrix pipelines currently approved by the US Food and Drug Administration (FDA) for clinical trials are: [0003] (1) For the first time, Nicolas L'Heureux et al. applied the acellular matrix tissue engineering blood vessel without artificial synthetic materials in clinical practice. The patency rate of venous fistula phase I clinical trial was 78% (7 / 9) at 1 month, and 60% (5 / 8) at 6 months. Although Nicolas L’Heureux and others have prepared autologous acellular matrix pipelines...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L27/54A61L27/50A61L27/36A61L33/08A61L33/00
CPCA61L27/36A61L27/54A61L27/3625A61L27/3679A61L27/3687A61L27/507A61L33/0011A61L2300/236A61L2300/42A61L2430/40
Inventor 邱雪峰董念国王滔
Owner 海迈医疗科技(苏州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap